Project Grant R43DA050405

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $603,406 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Research Triangle Institute (RTI International) to develop GPR139 antagonists for enhancing the analgesic efficacy of opioid medications. The project aims to optimize the potency, selectivity, and drug-like properties of GPR139 antagonist compounds through medicinal chemistry and in vitro...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $327,864 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Opsin Biotherapeutics Inc. to develop an optogenetic pain modulator for non-opioid chronic pain management. The project aims to optimize the optical delivery and wireless stimulation device for the Multi-Characteristic Opsin (MCO) that can be delivered to pain-sensing neurons and stimulated to minimize pain perception. The...

This federal Project Grant award of $1,587,553 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development and characterization of novel, central nervous system (CNS)-penetrant 5-HT3 receptor antagonists as potential treatments for neuropathic pain. The primary awardee, The Washington University in St. Louis, is collaborating with the University of Health Sciences and Pharmacy in St. Louis...

This $4,219,969 Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop FZ006, a novel oral biotherapeutic to treat chronic visceral pain associated with irritable bowel syndrome (IBS). FZ006 is an engineered probiotic yeast (Saccharomyces boulardii) that secretes a neutralizing antibody against tumor necrosis factor-alpha, a key inflammatory mediator implicated in...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $945,966 to Rowan University to research the potential of the GPR83 pathway as a target for reducing the abuse liability of opioid medications. The key objectives are to: Determine the physical interactions between the neuropeptide PEN-activated GPR83 receptor and the mu-opioid receptor (MOR) in the periaqueductal gray region of the brain. Define...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $220,668 to Amalgent Therapeutics, Inc. to support the development of a novel opioid adjuvant. The adjuvant is designed to increase the pain-relieving efficacy of opioid medications, allowing for reduced opioid dosing and mitigating the risks of opioid abuse, dependence, and tolerance. The award funds two specific aims: 1) investigating the...

The federal Cooperative Agreement award UG3DA059278, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop SBS-226, a novel mu-opioid receptor (MOR) agonist and delta-opioid receptor (DOR) antagonist, for the treatment of opioid use disorder (OUD). The $11,872,077 project will support comprehensive IND-enabling development and a Phase 1 clinical trial for SBS-226, a non-addictive compound demonstrated to have...

This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research into a novel, non-opioid spinal analgesic mechanism for the treatment of high-impact chronic pain. The $664,772 award to the University of Texas Southwestern Medical Center aims to dissect the signaling pathway involving the neurotensin receptor 2 (NTSR2)...

This Project Grant award, totaling $444,125 and awarded by the National Institute of Neurological Disorders and Stroke (NINDS), is funding research under the Drug Use and Addiction Research Programs (CFDA 93.279) to explore the function of the LRRC55 protein in pain transmission. The primary recipient, Duke University, will investigate the role of LRRC55 in regulating ion channels involved in chronic pain, with the goal of identifying novel, non-opioid therapeutic targets to treat pain. Key...

Regulonix LLC was awarded a $1,258,410 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), to support research under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). Through this one-year award ending August 31, 2022, Regulonix will partner with the University of Arizona to characterize inhibitors of the neuropilin-1 (NRP-1) receptor for potential...